NHC
National HealthCare Corporation
NHC has the edge over NVO overall, supported by stronger fundamentals.
NVO
Novo Nordisk A/S
NVO has slightly lower modeled downside risk, despite its lower overall score.
NHC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Stable |
NHC's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
NHC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 12x | $88.68 | -58% |
| Fair | 22x | $156 | -26% |
| Current | 29x | $211 | — |
| Expensive | 33x | $242 | +15% |
Historical ranges are pointers, not guarantees.
NHC's PE is in its expensive range at 29x.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over NHC in the historical PE scenario, which offers more potential upside but is not a forecast.
NHC Forward outlook
There aren't enough analyst estimates for NHC to show an outlook.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
NHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $7.24 | +12% |
| Q2 2026 | $8.89 | +33% |
| Q1 2026 | $7.87 | +14% |
| Q4 2025 | $7.67 | +17% |
| Q3 2025 | $6.47 | -19% |
| Q2 2025 | $6.70 | +13% |
| Q1 2025 | $6.91 | +31% |
| Q4 2024 | $6.53 | +50% |
NHC's earnings per share have fallen from their peak: $7.24 over the past year, against $10.82 in mid-2021.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over NHC on earnings, with more consistent year-over-year improvement.
NHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $408M | +6.6% |
| Q2 2026 | $408M | +8.8% |
| Q1 2026 | $381.8M | +2.2% |
| Q4 2025 | $386.5M | +4.6% |
| Q3 2025 | $382.7M | +12% |
| Q2 2025 | $374.9M | +25% |
| Q1 2025 | $373.7M | +26% |
| Q4 2024 | $369.4M | +23% |
NHC's revenue has grown year over year for 14 quarters in a row: $408M last quarter, up 6.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 10% | +2 points |
| Q2 2026 | 12% | +2.9 points |
| Q1 2026 | 8.4% | +0.2 points |
| Q4 2025 | 8.6% | +1.4 points |
| Q3 2025 | 7.9% | +1.8 points |
| Q2 2025 | 9.1% | +1.6 points |
| Q1 2025 | 8.2% | +3 points |
| Q4 2024 | 7.2% | +0.5 points |
NHC's operating margin was 10% last quarter, up 2 points from the same quarter a year ago, near the top of its range since 2019.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over NHC on profitability, with a higher operating margin.
NHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $99.2M | +76% |
| Q2 2026 | $30.7M | -42% |
| Q1 2026 | $52.9M | +60% |
| Q4 2025 | $6.4M | +38% |
| Q3 2025 | $56.5M | +98% |
| Q2 2025 | $52.6M | +23% |
| Q1 2025 | $33.1M | +797% |
| Q4 2024 | $4.6M | -73% |
NHC has the edge over NVO on cash flow, with more consistent year-over-year improvement.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
NHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +101K shares |
| 1 year | +1.9% | +300K shares |
| 3 years | +4.2% | +640K shares |
| 5 years | +3.9% | +601K shares |
| Available history | +3.9% | +605K shares |
NHC has 16M diluted shares, up 1.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.1M |
| Q2 2026 | $7.2M |
| Q1 2026 | $16.3M |
| Q4 2025 | $5.2M |
| Q3 2025 | $3.2M |
| Q2 2025 | $4.7M |
| Q1 2025 | $1.7M |
| Q4 2024 | — |
NHC spent $30M buying back its own shares over the past year, about three times what it spent the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over NHC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
NHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | -0.2x | Net Cash |
| Q1 2026 | -0.5x | Net Cash |
| Q4 2025 | -0.3x | Net Cash |
| Q3 2025 | -0.4x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | 0.3x | Very low |
| Q4 2024 | 0.5x | Very low |
NHC's net debt is about 2.1 years of its operating earnings (EBITDA), after holding more cash than debt a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over NHC on leverage, with a lower net debt burden relative to earnings.
NHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.0 | Neutral |
| Stochastic | 15.5 | Oversold |
NHC's weekly RSI is 50 (neutral) and its Stochastic is 15 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
NHC PE vs Healthcare Sector
| Metric | NHC | Sector median | Relative |
|---|---|---|---|
| PE | 29x | 26x | 13% above |
| PE % | 73 | 29 | 44 pts above |
NHC is trading at 29x earnings, a 13% premium to the Healthcare sector's median of 26x.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over NHC on valuation relative to its sector.
NHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $223.3 | 5.6% below |
| 20 week MA | $222.8 | 5.4% below |
| 50 week MA | $188.1 | 12% above |
| 100 week MA | $147.3 | 43% above |
| 200 week MA | $117.5 | 79% above |
NHC has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
NHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $85.0 | $66.3 | -22% |
| 2021 | $66.3 | $67.7 | +2.2% |
| 2022 | $67.7 | $61.8 | -8.8% |
| 2023 | $61.8 | $92.4 | +50% |
| 2024 | $92.4 | $109.6 | +19% |
| 2025 | $109.6 | $138.7 | +27% |
| 2026 YTD | $138.7 | $210.8 | +52% |
NHC has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.